{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:59:51Z","timestamp":1781650791637,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      We aimed to demonstrate that\n                      <jats:italic>MYC<\/jats:italic>\n                      amplification in adenocarcinomas of the stomach (GC) and gastroesophageal junction (GEJ) is of tumor biological significance and exhibits intratumoral heterogeneity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>MYC<\/jats:italic>\n                      amplification was analyzed by fluorescence in situ hybridization using whole mount tissue sections obtained from resection specimens of 460 chemotherapy naive (surgery only) and 122 neoadjuvantly treated GC-GEJs. The extent of intratumoral heterogeneity was quantified and a MYC score was established.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The number of\n                      <jats:italic>MYC<\/jats:italic>\n                      -amplified tumor cells varied largely ranging from few scattered single cells (&lt;\u200920 per high power field) up to all tumor cells. MYC score 1 was found in 276 cases (47.4%). Split by cohorts, 199 (43.3%) tumors of the chemotherapy na\u00efve (surgery only) and 77 (63.1%) tumors of the neoadjuvant cohort were sorted into the category MYC Score 1. These tumors were frequently located in the gastroesophageal junction, showed non-diffuse differentiation according to Lauren, and favored male sex. Additionally, correlations with higher T- and N category were observed. Overall survival and tumor-specific survival correlated negatively with the MYC score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>MYC<\/jats:italic>\n                      amplification is common in GC-GEJ, most often heterogeneously distributed, and associated with reduced therapy response. Most interestingly,\n                      <jats:italic>MYC<\/jats:italic>\n                      amplification is far more common in men, providing evidence for sex-specific disease mechanisms, and in tumors that show little response to neoadjuvant chemotherapy, suggesting a link to therapy resistance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16074-3","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:44:22Z","timestamp":1777013062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MYC amplification is common in cancer of the stomach and gastroesophageal junction, correlates with male sex and reduced response to neoadjuvant therapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Ole","family":"Biegler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Michael","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen Markus","family":"Heckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"L\u00fcschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6cken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"3","key":"16074_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"16074_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/gutjnl-2019-320234","volume":"69","author":"M Arnold","year":"2020","unstructured":"Arnold M, Park JY, Camargo MC, Lunet N, Forman D, Soerjomataram I. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020;69(5):823\u20139.","journal-title":"Gut"},{"issue":"10","key":"16074_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"issue":"2","key":"16074_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/ijc.28999","volume":"136","author":"M Plummer","year":"2015","unstructured":"Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136(2):487\u201390.","journal-title":"Int J Cancer"},{"issue":"10251","key":"16074_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635\u201348.","journal-title":"Lancet"},{"issue":"10184","key":"16074_CR6","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"issue":"3","key":"16074_CR7","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer Clin. 2021;71(3):264\u201379.","journal-title":"CA Cancer Clin"},{"issue":"3","key":"16074_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/or.2015.4528","volume":"35","author":"DD Yuan","year":"2016","unstructured":"Yuan DD, Zhu ZX, Zhang X, Liu J. Targeted therapy for gastric cancer: Current status and future directions (Review). Oncol Rep. 2016;35(3):1245\u201354.","journal-title":"Oncol Rep"},{"issue":"1","key":"16074_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","volume":"8","author":"E Pectasides","year":"2018","unstructured":"Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, et al. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018;8(1):37\u201348.","journal-title":"Cancer Discov"},{"issue":"1","key":"16074_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41467-019-13915-7","volume":"11","author":"K von Loga","year":"2020","unstructured":"von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, et al. Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. Nat Commun. 2020;11(1):139.","journal-title":"Nat Commun"},{"issue":"1","key":"16074_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13073-021-00975-y","volume":"13","author":"C R\u00f6cken","year":"2021","unstructured":"R\u00f6cken C, Amallraja A, Halske C, Opasic L, Traulsen A, Behrens HM, et al. Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine. Genome Med. 2021;13(1):177.","journal-title":"Genome Med"},{"issue":"24","key":"16074_CR12","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","volume":"79","author":"R Dalla-Favera","year":"1982","unstructured":"Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7824\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"16074_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1006\/excr.1999.4686","volume":"253","author":"CV Dang","year":"1999","unstructured":"Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, et al. Function of the c-Myc oncogenic transcription factor. Exp Cell Res. 1999;253(1):63\u201377.","journal-title":"Exp Cell Res"},{"issue":"1","key":"16074_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/MCB.19.1.1","volume":"19","author":"CV Dang","year":"1999","unstructured":"Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19(1):1\u201311.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"16074_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22\u201335.","journal-title":"Cell"},{"issue":"3","key":"16074_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.cels.2018.03.003","volume":"6","author":"FX Schaub","year":"2018","unstructured":"Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, et al. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst. 2018;6(3):282\u2013e300282.","journal-title":"Cell Syst"},{"issue":"4","key":"16074_CR17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/2159-8290.CD-22-0796","volume":"13","author":"LS Pongor","year":"2023","unstructured":"Pongor LS, Schultz CW, Rinaldi L, Wangsa D, Redon CE, Takahashi N, et al. Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes. Cancer Discov. 2023;13(4):928\u201349.","journal-title":"Cancer Discov"},{"issue":"12","key":"16074_CR18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1054\/bjoc.2000.1522","volume":"83","author":"SL Deming","year":"2000","unstructured":"Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer. 2000;83(12):1688\u201395.","journal-title":"Br J Cancer"},{"issue":"6","key":"16074_CR19","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/0016-5085(86)90208-8","volume":"91","author":"RJ Alexander","year":"1986","unstructured":"Alexander RJ, Buxbaum JN, Raicht RF. Oncogene alterations in primary human colon tumors. Gastroenterol. 1986;91(6):1503\u201310.","journal-title":"Gastroenterol"},{"issue":"4B","key":"16074_CR20","first-page":"2909","volume":"26","author":"RR Burbano","year":"2006","unstructured":"Burbano RR, Assumpcao PP, Leal MF, Calcagno DQ, Guimaraes AC, Khayat AS, et al. C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res. 2006;26(4B):2909\u201314.","journal-title":"Anticancer Res"},{"issue":"38","key":"16074_CR21","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.3748\/wjg.v12.i38.6207","volume":"12","author":"DQ Calcagno","year":"2006","unstructured":"Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S, et al. Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma. World J Gastroenterol. 2006;12(38):6207\u201311.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"16074_CR22","doi-asserted-by":"publisher","first-page":"e64420","DOI":"10.1371\/journal.pone.0064420","volume":"8","author":"CR de Souza","year":"2013","unstructured":"de Souza CR, Leal MF, Calcagno DQ, Costa Sozinho EK, Borges Bdo N, Montenegro RC, et al. MYC deregulation in gastric cancer and its clinicopathological implications. PLoS ONE. 2013;8(5):e64420.","journal-title":"PLoS ONE"},{"issue":"2","key":"16074_CR23","doi-asserted-by":"publisher","first-page":"e21221","DOI":"10.5812\/ircmj.21221","volume":"18","author":"M Khaleghian","year":"2016","unstructured":"Khaleghian M, Jahanzad I, Shakoori A, Emami Razavi A, Azimi C. Association Between Amplification and Expression of C-MYC Gene and Clinicopathological Characteristics of Stomach Cancer. Iran Red Crescent Med J. 2016;18(2):e21221.","journal-title":"Iran Red Crescent Med J"},{"key":"16074_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12876-015-0231-4","volume":"15","author":"P Stahl","year":"2015","unstructured":"Stahl P, Seeschaaf C, Lebok P, Kutup A, Bockhorn M, Izbicki JR, et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol. 2015;15:7.","journal-title":"BMC Gastroenterol"},{"key":"16074_CR25","doi-asserted-by":"crossref","unstructured":": Cancer Genome Atlas Research N, Analysis Working Group, Asan U, Agency BCC, Brigham I et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017; 541(7636):169\u2013175.","DOI":"10.1038\/nature20805"},{"issue":"7517","key":"16074_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"7","key":"16074_CR27","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521\u201330.","journal-title":"Cancer"},{"issue":"5","key":"16074_CR28","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s10120-025-01624-8","volume":"28","author":"SM Heckl","year":"2025","unstructured":"Heckl SM, Behrens HM, Ebert U, Ulase D, Richter F, Becker T, et al. Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world. Gastric Cancer. 2025;28(5):982\u201392.","journal-title":"Gastric Cancer"},{"key":"16074_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","volume":"64","author":"P Lauren","year":"1965","unstructured":"Lauren P. The two histologic main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31\u201349.","journal-title":"Acta Pathol Microbiol Scand"},{"key":"16074_CR30","doi-asserted-by":"crossref","unstructured":"Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours 8. Wiley Blackwell; 2016.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"issue":"3","key":"16074_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/PDM.0b013e318284188e","volume":"22","author":"V Warneke","year":"2013","unstructured":"Warneke V, Behrens HM, Haag J, Balschun K, B\u00f6ger C, Becker T, et al. Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol. 2013;22(3):127\u201337.","journal-title":"Diagn Mol Pathol"},{"issue":"5","key":"16074_CR32","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/annonc\/mdx047","volume":"28","author":"C B\u00f6ger","year":"2017","unstructured":"B\u00f6ger C, Kr\u00fcger S, Behrens HM, Bock S, Haag J, Kalthoff H, et al. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations. Ann Oncol. 2017;28(5):1005\u201314.","journal-title":"Ann Oncol"},{"issue":"3","key":"16074_CR33","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/annonc\/mds528","volume":"24","author":"VS Warneke","year":"2013","unstructured":"Warneke VS, Behrens HM, B\u00f6ger C, Becker T, Lordick F, Ebert MP, et al. Her2\/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol. 2013;24(3):725\u201333.","journal-title":"Ann Oncol"},{"issue":"2","key":"16074_CR34","doi-asserted-by":"publisher","first-page":"241253","DOI":"10.1111\/his.12745","volume":"68","author":"ML Metzger","year":"2016","unstructured":"Metzger ML, Behrens HM, B\u00f6ger C, Haag J, Kruger S, R\u00f6cken C. MET in gastric cancer - discarding a 10% cutoff rule. Histopathology. 2016;68(2):241253.","journal-title":"Histopathology"},{"key":"16074_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.humpath.2020.09.006","volume":"105","author":"I Schoop","year":"2020","unstructured":"Schoop I, Maleki SS, Behrens HM, Kr\u00fcger S, Haag J, R\u00f6cken C. p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort. Hum Pathol. 2020;105:53\u201366.","journal-title":"Hum Pathol"},{"key":"16074_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/PAI.0000000000000264","volume":"25","author":"M Mathiak","year":"2017","unstructured":"Mathiak M, Warneke VS, Behrens HM, Haag J, B\u00f6ger C, Kr\u00fcger S, et al. Clinicopathologic characteristics of microsatellite instable gastric carcinomas revisited: urgent need for standardization. Appl Immunohistochem Mol Morphol. 2017;25:12\u201324.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"16074_CR37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00428-024-03826-4","volume":"485","author":"D Ulase","year":"2024","unstructured":"Ulase D, Behrens HM, R\u00f6cken C. Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study. Virchows Arch. 2024;485(3):527\u201334.","journal-title":"Virchows Arch"},{"key":"16074_CR38","doi-asserted-by":"crossref","unstructured":"Ulase D, Heckl S, Behrens HM, Kr\u00fcger S, R\u00f6cken C. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference. Histopathology. 2020; 76(3):433\u2013446.","DOI":"10.1111\/his.13997"},{"issue":"1","key":"16074_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Statist Soc B. 1995;57(1):289\u2013300.","journal-title":"J R Statist Soc B"},{"issue":"12","key":"16074_CR40","doi-asserted-by":"publisher","first-page":"e51862","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7(12):e51862.","journal-title":"PLoS ONE"},{"issue":"1","key":"16074_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00432-019-03082-z","volume":"146","author":"F Clausen","year":"2020","unstructured":"Clausen F, Behrens HM, Kr\u00fcger S, R\u00f6cken C. Sexual dimorphism in gastric cancer: tumor-associated neutrophils predict patient outcome only for women. J Cancer Res Clin Oncol. 2020;146(1):53\u201366.","journal-title":"J Cancer Res Clin Oncol"},{"key":"16074_CR42","doi-asserted-by":"crossref","unstructured":"Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D et al. MYC Deregulation in primary human cancers. Genes (Basel). 2017;8(6).","DOI":"10.3390\/genes8060151"},{"issue":"11","key":"16074_CR43","first-page":"5031","volume":"32","author":"JS Choi","year":"2012","unstructured":"Choi JS, Seo J, Jung EJ, Kim EJ, Lee GK, Kim WH. c-MYC amplification in mucinous gastric carcinoma: a possible genetic alteration leading to deeply invasive tumors. Anticancer Res. 2012;32(11):5031\u20137.","journal-title":"Anticancer Res"},{"issue":"1","key":"16074_CR44","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1038\/s41467-020-17359-2","volume":"11","author":"CH Li","year":"2020","unstructured":"Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N, Subtypes PT, et al. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11(1):4330.","journal-title":"Nat Commun"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16074-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16074-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16074-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:38:51Z","timestamp":1781649531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16074-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16074"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16074-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical approval was received from the ethical review board (D 549\/20; date of approval: 10.08.2020) of the University Hospital Schleswig-Holstein, Kiel, Germany. This study was performed in accordance with the Declaration of Helsinki. Patient privacy rights were observed and informed consent was obtained. After study inclusion, all patient-related data were pseudonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"525"}}